At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Pemetrexeddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Home Delivery of Pemetrexed as Maintenance Treatment in Patients Who Have Not Progressed After Induction Therapy for Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Feasibility Study
In Brief
A Phase 2 clinical trial evaluating Pemetrexed for Nonsquamous Non-Small Cell Neoplasm of Lung and 2 related conditions. Completed, enrolled 52 participants across 9 sites in 2 countries.
Detailed Summary
The main purpose for this study is to answer the following research questions: * Can pemetrexed be administered safely at the participant's home, using the same treatment procedure as in a hospital setting? * Will the participant be satisfied with home care? * How might this impact the participant's quality of life? * What are the required medical resources needed to give pemetrexed in a home setting?
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonsquamous Non-Small Cell Neoplasm of Lung, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer Stage IIIB
CountriesSweden, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartDec 2011
Primary CompletionSep 2013
TodayJul 2026
First PostedNov 17, 2011
Enrollment StartDec 1, 2011
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.6 years ago
Interventions
Pemetrexeddrug
Administered intravenously